Orforglipron

1 Identity

Non-peptide small molecule. A multi-ring heteroaromatic structure incorporating benzimidazole and fused azine systems, difluorinated, originating at Chugai Pharmaceutical and developed by Eli Lilly and Company. It is cataloged with the incretin and amylin receptor agonists because that target class is what governs how it is filed, notwithstanding that its chemistry is small-molecule; the taxonomy follows the pharmacological class where that class is what governs, and the panel follows the chemistry. Recording it as "not a peptide" is accurate but is not the operative fact about it. Chugai precursor designations appear in the patent and early literature. Not a peptide and not a synonym for any peptide GLP-1 receptor agonist: semaglutide, tirzepatide, retatrutide, liraglutide, survodutide.

Sequence

No sequence — not a peptide, and no peptide bond is present. See the molecular class note. The clinical form is the calcium salt, orforglipron calcium; salt stoichiometry, hydration state and the full stereochemical descriptor set are deliberately not asserted here. They are declared per lot on the certificate, and no structural claim is printed that the certificate does not carry.

Molecular formula

C48H48F2N10O5 (free base). Calcium salt stoichiometry and hydration state not established and not asserted.

Average mass

882.974 Da for the free base, from C48H48F2N10O5 on IUPAC 2021 abridged conventional atomic weights (C 12.011, H 1.008, F 18.998403163, N 14.007, O 15.999). The same formula on the pre-2021 table gives 882.955; both are right on their own basis, and the catalog standardizes on the 2021 table. Published supplier figures sit either side: 882.97 on some listings, and a formula weight of 883.0 on others. No mass is asserted for the calcium salt.

Monoisotopic mass

882.3777 Da neutral monoisotopic for the free base, from C48H48F2N10O5. [M+H]+ 883.3850; [M-H]- 881.3705. The instrumentally decisive point is not the number but the ion: a molecule of this size gives a singly charged electrospray ion, whereas every peptide it might be substituted with gives a multiply charged charge-state envelope. No monoisotopic mass is asserted for the calcium salt.

Salt / variant note

A single molecule at the free-base level — no close structural analog is sold under this name — but two substitution axes are live and both are detectable without ambiguity. (1) class swap, the real risk in this channel, and it shows in a single glance at the spectrum: material offered under incretin names is routinely a peptide GLP-1 receptor agonist relabeled. Semaglutide is an acylated 31-residue peptide of approximately 4,113 Da average, tirzepatide approximately 4,814 Da, retatrutide approximately 4,731 Da — four to five times the mass of an 883 Da small molecule — and they behave completely differently on the instrument, giving a multiply charged electrospray envelope with a charge-state ladder where this compound gives a singly charged ion. A deconvoluted mass in the 4,000 to 5,000 Da band, or a raw spectrum showing a charge-state series, is not this compound under any reading. (2) salt versus free base: orforglipron calcium and orforglipron free base do not report the same molecular weight, and no certificate is interpretable unless it states which it describes and, if the salt, the stoichiometry and the hydration state. Danuglipron, the nearest same-class oral small-molecule confusable, is a materially lighter molecule; no figure is asserted for it here.

2 Class & testing panel

Form

Single article

Testing panel

P6 — panel definition

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists and is the largest and highest-quality human evidence base of any compound in this catalog by a wide margin: a sponsor-run program of registered Phase 1, Phase 2 and Phase 3 trials on ClinicalTrials.gov with results published in peer-reviewed journals, supported by a full preclinical package.

4 Storage & specification

Storage

Sealed, light-protected containers with a desiccant, stored dry and away from heat at the storage temperature carried on the specification. The specification is written against the form received, free base or calcium salt, because the two do not report the same molecular weight; the salt's stoichiometry and hydration state are taken from the certificate for the lot and carried with it.

Shelf life

The article is dated from the date of manufacture on the certificate for the lot, and the retest interval printed on its specification is confirmed by pull under the company's ICH-format stability program rather than carried over unexamined from the supplier. The attributes that limit that interval are assay content against the declared form, water content, related substances and any new peak above 0.10 percent, and, for the calcium salt, the stated stoichiometry and hydration state; the lot is handled first-expiry-first-out on that date.